Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Propensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...

There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...